Skip to main content

Broadly protective anti-viral vaccines

New Content Item
(Image by Angelo Esslinger from Pixabay)


The rapid development of broadly protective anti-viral vaccines has been considered an intervention strategy of primary importance to reduce the spread of viruses – both endemic viruses like influenza, representing a health and economic burden, and new or emerging viruses with pandemic potential. Platforms should be developed to allow producing broadly protective vaccines either directly or after further adaptation to the newly emerged pandemic virus.

Such vaccines should provide protection against several members of the same virus family. Influenza and coronaviruses are not the only pathogens that could be targeted by a universal vaccine approach. There are several other virus families that harbour viruses with pandemic potential, such as HIV, Hepatitis, yellow fever, Ebola, Zika, Dengue, meningitis. Furthermore, universal vaccines against hepatitis C and HIV are still unavailable.

To achieve this goal, there is an urgent need for more research on understanding correlates of broad protection within these virus families, as well as studies exploring vaccine platforms that are designed to induce such protective responses. Research is also ongoing on the opportunities of using existing vaccines against non-related pathogens, like BCG, Polio- or MMR vaccine, to boost innate immunity as a measure to mitigate the outcome of a pandemic virus infection.

This new cross-journal thematic series welcomes research, reviews, methodology articles and short reports exploring recent developments and promising new research avenues for the development of broadly protective anti-viral vaccines, as well as hurdles and limitations. Studies considering aspects of health economics and health services are also in scope in this series, including research funding, international cooperation, and global investment for better pandemic preparedness.


The following journals are accepting submissions to the series:

Virology Journal

One Health Outlook


Manuscripts should be formatted according to the individual journals instructions for authors and submitted via the online submission system. Please indicate clearly in the title page that the manuscript is to be considered for the thematic series ‘Broadly protective anti-viral vaccines’. 

Manuscripts will be peer-reviewed independently by the respective journal. Accepted articles will be published online on a continuous basis.

Pre-submission enquiries are welcome. If you have questions before submitting your manuscript, please contact us.

Deadline for submissions: 30 June 2022

  1. In recent years, the traditional cognition of immunological memory being specific to adaptive immunity has been challenged. Innate immunity can mount enhanced responsiveness upon secondary stimulation, and a p...

    Authors: Shiwei Hu, Danhong Xiang, Xinlu Zhang, Lan Zhang, Shengjie Wang, Keyi Jin, Liangshun You and Jian Huang
    Citation: Virology Journal 2022 19:210
  2. Epstein-Barr virus (EBV) is a wide-spread human herpesvirus that is highly associated with infectious mononucleosis and several malignancies. Evaluation of EBV neutralizing antibody titers is important for ser...

    Authors: Ling Zhong, Claude Krummenacher, Wanlin Zhang, Junping Hong, Qisheng Feng, Qinjian Zhao, Yixin Chen, Mu-Sheng Zeng, Yi-Xin Zeng, Miao Xu and Xiao Zhang
    Citation: Virology Journal 2022 19:196
  3. The presentation of Guillain–Barré syndrome (GBS) caused by Japanese encephalitis virus (JEV) is uncommon, although clusters of GBS cases were observed in China in 2018. The underlying mechanism is unclear, pa...

    Authors: Sheng Liu, Jinyong Wang, Jun Yang and Ying Wen
    Citation: Virology Journal 2022 19:139
  4. Vaccination against HCV is an effective measure in reduction of virus-related public health burden and mortality. However, no prophylactic vaccine is available as of yet. DNA-based immunization is a promising ...

    Authors: Ali Shayeghpour, Roya Kianfar, Parastoo Hosseini, Mehdi Ajorloo, Sepehr Aghajanian, Mojtaba Hedayat Yaghoobi, Tayebeh Hashempour and Sayed-Hamidreza Mozhgani
    Citation: Virology Journal 2021 18:248